Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Account Payables (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 10 years of Change in Account Payables data on record, last reported at -$1.4 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 64.82% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached $6.6 million, up 9089.04%, while the annual FY2025 figure was $6.6 million, 9089.04% up from the prior year.
  • Change in Account Payables reached -$1.4 million in Q4 2025 per VRDN's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $8.0 million in Q3 2022 and bottomed at -$6.6 million in Q1 2023.
  • Average Change in Account Payables over 5 years is $381400.0, with a median of $460000.0 recorded in 2024.
  • Peak YoY movement for Change in Account Payables: tumbled 21541.94% in 2023, then surged 2812.96% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at -$1.4 million in 2021, then surged by 224.11% to $1.7 million in 2022, then tumbled by 186.88% to -$1.5 million in 2023, then tumbled by 158.77% to -$3.9 million in 2024, then skyrocketed by 64.82% to -$1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$1.4 million in Q4 2025, $1.5 million in Q3 2025, and $4.6 million in Q2 2025.